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AbsTRACT
Objective To evaluate the efficacy of denosumab 
in suppressing joint destruction when added to 
conventional synthetic disease-modifying antirheumatic 
drug (csDMaRD) therapy in patients with rheumatoid 
arthritis (Ra).
Methods This was a multi-centre, randomised, 
double-blind, parallel-group, placebo-controlled 
phase 3 study in Japan. Patients with Ra aged ≥20 
years receiving csDMaRDs were randomly assigned 
(1:1:1) to denosumab 60 mg every 3 months (Q3M), 
denosumab 60 mg every 6 months (Q6M) or placebo. 
The change in the modified total sharp score (mTss) 
and effect on bone mineral density (BMD) at 12 
months was evaluated.
Results in total, 654 patients received the trial 
drugs. Denosumab groups showed significantly less 
progression of joint destruction. The mean changes 
in the mTss at 12 months were 1.49 (95% Ci 0.99 
to 1.99) in the placebo group, 0.99 (95% Ci 0.49 to 
1.49) in the Q6M group (p=0.0235) and 0.72 (95% 
Ci 0.41 to 1.03) in the Q3M group (p=0.0055). The 
mean changes in bone erosion score were 0.98 (95% 
Ci 0.65 to 1.31) in the placebo group, 0.51 (95% Ci 
0.22 to 0.80) in the Q6M group (p=0.0104) and 0.22 
(95% Ci 0.09 to 0.34) in the Q3M group (p=0.0001). 
no significant between-group difference was observed 
in the joint space narrowing score. The per cent change 
in lumbar spine (l1–l4) BMD in the placebo, Q6M 
and Q3M groups were −1.03%, 3.99% (p<0.0001) 
and 4.88% (p<0.0001). no major differences were 
observed among safety profiles.
Conclusions Denosumab inhibits the progression of 
joint destruction, increases BMD and is well tolerated in 
patients with Ra taking csDMaRD.
InTROduCTIOn
Rheumatoid arthritis (RA) is characterised by 
inflammatory synovitis that causes joint cartilage 
and bone destruction1 2 and increases fracture risk 
through bone erosion and osteoporosis.3 4 Bone 
damage is localised to the periarticular cortical 
areas of inflamed joints in early RA, but oste-
oporosis extends to the diaphyses becoming 
generalised in advanced stages. On infiltration 
into the periarticular region, activated T and B 
cells express two essential osteoclast mediators, 
Key messages
What is already known about this subject?
 ► Denosumab, an antibody targeting receptor 
activator of nuclear factor κB ligand, can 
successfully inhibit the progression of bone 
erosion and increase bone mineral density 
(BMD) in patients with rheumatoid arthritis (RA) 
receiving methotrexate.
What does this study add?
 ► The DESIRABLE study is the largest study 
performed to date investigating the efficacy of 
denosumab in patients with RA.
 ► Denosumab significantly inhibits the 
progression of joint destruction: denosumab 
inhibited the progression of the modified total 
Sharp score and erosion scores and led to an 
increase in BMD but did not affect the joint 
space narrowing or disease activity scores 
in patients with RA receiving conventional 
synthetic disease-modifying antirheumatic 
drugs (csDMARDs) (including methotrexate).
 ► Denosumab was generally well tolerated in 
patients receiving background treatment with 
csDMARDs.
How might this impact on clinical practice or 
future developments?
 ► Denosumab has potential as a novel therapeutic 
option for suppression of bone erosion and 
bone loss in patients with RA with or without 
concomitant osteoporosis, particularly in 
patients who are contraindicated for biological 
disease-modifying antirheumatic drugs 
(bDMARDS).
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one being the receptor activator of nuclear factor κB ligand 
(RANKL).1 2 5 The proliferated synovium erodes from the 
osteochondral junction into the bone tissue, with osteoclasts 
destroying the local joint site.
Disease-modifying antirheumatic drugs (DMARDs) modu-
late the inflammatory immune responses slowing radiographic 
damage.6 Conventional synthetic DMARDs (csDMARDs) are 
commonly prescribed for patients with RA, although meth-
otrexate remains the gold standard. Biological DMARDs 
(bDMARDs) are also used to target specific proteins and can 
potently suppress RA disease; however, they may cause serious 
infection. Some patients do not respond fully to bDMARDs,1 
possibly because their joint destruction is unconnected to the clin-
ical scores of inflammation.7 These issues may be compounded 
by the worsening of RA pathology by steroid-induced and disuse 
osteoporosis.8
RANKL is essential for osteoclast development, activation and 
survival.9 Denosumab, a fully human monoclonal IgG2 antibody, 
binds and neutralises the activity of human RANKL suppressing 
bone resorption10 and may also prevent progression of bone 
erosion. Two phase 2 studies of denosumab have been conducted 
in patients with RA receiving methotrexate: in a study in the 
USA and Canada, denosumab 60 or 180 mg was administered 
every 6 months,11 while in a Japanese study, denosumab 60 mg 
was administered every 2, 3 or 6 months.12 Both demonstrated 
significant inhibition of bone erosion progression compared with 
placebo. Therefore, we conducted this phase 3 study to evaluate 
the effect of denosumab on the progression of joint damage in 
patients with RA being treated with csDMARDs.
MeTHOds
study design and patients
This was a randomised, double-blind, parallel-group, place-
bo-controlled phase 3 study conducted at 104 hospitals in Japan. 
We enrolled patients aged ≥20 years who fulfilled the 1987 
American College of Rheumatology (ACR) criteria13 or 2010 
ACR/European League Against Rheumatism criteria14 for RA, 
who had RA for 6 months to <5 years and were receiving treat-
ment with one or more csDMARDs. Based on a treat-to-target 
strategy, investigators adjusted csDMARD dosages for RA disease 
activity and/or added other treatments as appropriate (including 
nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids 
and csDMARDs such as salazosulfapyridine, bucillamine and 
tacrolimus in addition to methotrexate). Eligible patients had 
bone erosions (≥1) on radiographs or met the following criteria: 
C-reactive protein (CRP) levels of ≥1.0 mg/dL or an erythrocyte 
sedimentation rate (ESR) of ≥28 mm/hour, and positive anticy-
clic citrullinated peptide antibodies or rheumatoid factor (>20 
IU/mL). The main exclusion criteria were RA functional class 
IV15 and previous or current treatment of RA with any biolog-
ical agents. Use of bisphosphonates, parathyroid hormones, oral 
glucocorticoids (prednisolone equivalent doses of >10 mg/day), 
biologics and tofacitinib6 were prohibited. However, hormone 
replacement therapy was allowed. Participants continued 
csDMARDs treatment and received ≥600 mg/day calcium with 
vitamin D.
Treatment and randomisation
The study drugs were denosumab (one prefilled syringe 
containing 1 mL of a sterile colourless solution of denosumab 60 
mg) and denosumab-matching placebo. Patients received either 
denosumab or placebo at 0, 3, 6 and 9 months.
Patients were stratified by baseline glucocorticoid use and 
randomly assigned in a 1:1:1 ratio by the Interactive Web 
Response System to receive one of three treatments for 12 
months: subcutaneous injection of denosumab 60 mg every 6 
months (Q6M), every 3 months (Q3M) or placebo. Assignment 
was done using the RANUNI function of SAS software (release 
V.9.1.3). Treatment was masked to patients, investigators, spon-
sors and trial personnel involved in measuring outcomes.
Collected patient data and assessments
Radiographs were taken at baseline, 6 months and 12 months 
and reviewed at a central imaging core lab. Independent readers 
evaluated hand and foot radiographs by the modified Sharp/van 
der Heijde method.16 Dual energy X-ray absorptiometry scans 
for bone mineral density (BMD) were performed to evaluate the 
lumbar spine (L1–L4) at baseline and 12 months, using Hologic 
Inc (USA) or GE Healthcare Ltd (UK) devices, and analyses were 
performed by BioClinica Inc (USA).
Clinical assessments at baseline, 6 months and 12 months 
included: physician’s and patient’s global assessment of disease 
activity by visual analogue scale (VAS), patient’s assessment 
of pain by VAS, Health Assessment Questionnaire-Disability 
Index (HAQ-DI),17 the 66-joint count for swollen joints and the 
68-joint count for tender joints. Blood and urine samples were 
obtained at fixed times and analysed at a central laboratory (LSI 
Medience Corporation, Tokyo, Japan) for haematology, blood 
biochemistry, serum C-telopeptide of type I collagen (CTX-I), 
urine C-telopeptide of type II collagen (CTX-II) and serum carti-
lage oligomeric matrix protein (COMP). CTX-II was adjusted 
for creatinine (CTX-II/Cre). The ACR response18 and disease 
activity score 28 (DAS28) CRP and ESR19 were calculated using 
these outcomes. Antidenosumab antibodies were assessed at 
baseline and 12 months by PPD Development, LLC (USA).
Outcome measures
The primary endpoint was the change in the modified total 
Sharp score (mTSS) from baseline to 12 months. Secondary 
endpoints were the changes from baseline to 6 months in the 
mTSS, changes in the erosion score at 6 months and 12 months, 
changes in the joint space narrowing (JSN) score at 12 months, 
per cent change in lumbar spine (L1–L4) BMD and the per cent 
change in markers of bone and cartilage metabolism. Explor-
atory variables of efficacy were assessed at 12 months: the 
proportion of patients without radiographic progression (change 
in the radiographic score of ≤0.5)20 according to the mTSS, the 
erosion score or the JSN score; the per cent change in BMD in 
the subgroup using glucocorticoids or the subgroup with base-
line osteoporosis; and the proportions of patients achieving 
an ACR20/50/70 response, a change in HAQ-DI, DAS28-CRP 
and DAS28-ESR from baseline. Safety was assessed by adverse 
events, laboratory tests and antidenosumab antibody levels and 
summarised according to the Medical Dictionary for Regulatory 
Activities (V.19.0).
statistical analyses
A sample size of 214 patients per group was estimated to be 
sufficient to obtain a power of 0.9 and a two-sided significance 
level of 0.05, assuming a probability of 0.593 that an individual 
change in mTSS score randomly drawn from the denosumab 
group is less than that from the placebo group (based on the 
phase 2 study12) and allowing 5% missing radiographic data. 
The full analysis set (FAS) for the efficacy analyses included 
all patients who received the assigned study drug and had an 
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Figure 1 Trial profile. *As one patient assigned to denosumab Q6M was administered placebo by mistake, the patient was included in the placebo 
group for safety analysis. †No mTSS measurements available at baseline or after the first administration of treatment. §207 (per-protocol set). ¶202 
(per-protocol set). ǂ200 (per-protocol set). mTSS, modified total Sharp score; PRT, protocol; Q3M, every 3 months; Q6M, every 6 months.
available mTSS score at baseline and at least one postbaseline 
assessment. Missing values for the radiographic score were 
imputed by linear extrapolation/interpolation. For other vari-
ables, no imputation was implemented.
The primary analysis compared the change in mTSS from 
baseline to 12 months between each denosumab group and 
the placebo group using the van Elteren stratified rank test 
adjusted for randomised strata (baseline glucocorticoid use). A 
hierarchical testing procedure was used to control the overall 
type I error at 0.05 for multiple comparisons of the primary 
endpoint; if there was a significant difference between the Q3M 
and placebo groups, comparison between the Q6M and placebo 
groups was formally tested. The same analysis method was used 
without multiple adjustments for the other radiographic score 
endpoints.
The proportions of patients without radiographic progression, 
with rapid radiographic progression (yearly progression of ≥5 
in mTSS), and of patients achieving ACR20/50/70 were analysed 
using the Cochran-Mantel-Haenszel test adjusted for randomised 
strata. In a post hoc analysis, the proportion of patients with 
minimal clinically important progression of HAQ-DI (change 
from baseline ≥0.22)21 was analysed by the same method. For 
changes from baseline in the DAS28-CRP, DAS28-ESR and 
HAQ-DI, comparisons of each denosumab group with the 
placebo group were performed using repeated measures analysis 
adjusted for treatment, visit, baseline value, randomised strata 
and treatment-by-visit interaction. The per cent changes from 
baseline in lumbar spine (L1–L4) BMD, including for subgroups, 
were assessed using the analysis of covariance model. Safety was 
analysed with the data set from patients who received at least 
one dose of the study drug. All analyses were conducted using 
SAS V.9.2.
ResulTs
Patient disposition and baseline characteristics
Between 29 October 2013 and 1 December 2015, 679 patients 
were randomised (figure 1). The FAS included 654 patients. 
One patient in the Q6M group received placebo by mistake, and 
therefore, that patient’s safety data were included in the placebo 
group. Baseline characteristics were similar across treatment 
groups (table 1). Dose adjustments of csDMARD and glucocor-
ticoid were made similarly among treatment groups.
efficacy
Regarding the primary endpoint, the mTSS increased in all 
groups despite csDMARD treatment (figure 2A). The Q3M and 
Q6M groups showed significantly smaller changes in the mTSS 
from baseline to 12 months versus the placebo group: mean 
changes were 1.49 (95% CI 0.99 to 1.99) in the placebo group; 
0.99 (95% CI 0.49 to 1.49), Q6M group (p=0.0235); and 0.72 
(95% CI 0.41 to 1.03), Q3M group (p=0.0055). Compared with 
placebo, changes in the mTSS from baseline to 6 months were 
significantly smaller in the Q6M and Q3M groups (p=0.0360 
and 0.0028, respectively) (figure 2A), as were the changes in 
the erosion score from baseline to 12 months (p=0.0104 and 
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Table 1 Baseline demographics and characteristics
denosumab
Placebo
(n=218)
60 mg Q6M
(n=217)
60 mg Q3M
(n=219)
Total
(n=654)
Female, n (%) 167 (76.6) 168 (77.4) 154 (70.3) 489 (74.8)
Age (years) 55.8 (11.70) 58.1 (12.30) 58.2 (12.04) 57.4 (12.04)
 ≥65 years, n (%) 55 (25.2) 77 (35.5) 69 (31.5) 201 (30.7)
BMI (kg/m2) 22.65 (3.49) 22.38 (3.68) 22.64 (3.62) 22.56 (3.59)
Osteoporosis, n (%) 44 (20.2) 42 (19.4) 46 (21.0) 132 (20.2)
Duration of RA (years) 2.07 (1.30) 2.20 (1.33) 2.20 (1.30) 2.16 (1.31)
RF status positive, n (%) 137 (62.8) 140 (64.5) 128 (58.4) 405 (61.9)
ACPA positive, n (%) 145 (66.5) 158 (72.8) 149 (68.0) 452 (69.1)
Modified total Sharp score (0–448) 13.14 (21.44) 15.92 (22.21) 15.17 (18.97) 14.75 (20.91)
Modified Sharp erosion score 
(0–280)
6.55 (10.58) 7.53 (10.11) 7.16 (9.41) 7.08 (10.04)
Modified Sharp JSN score (0–168) 6.59 (11.94) 8.39 (13.82) 8.01 (10.86) 7.66 (12.27)
Swollen joint count (0–66) 9.35 (4.43) 9.46 (4.88) 8.96 (4.30) 9.25 (4.54)
Tender joint count (0–68) 6.62 (6.39) 7.48 (8.20) 7.32 (8.00) 7.14 (7.57)
DAS28-CRP 3.43 (1.02) 3.62 (1.09) 3.52 (1.04) 3.52 (1.05)
  DAS28 >3.2, n (%) 119 (54.6) 141 (65.0) 138 (63.0) 398 (60.9)
CRP (mg/dL) 0.36 (0.57) 0.65 (1.25) 0.50 (1.03) 0.51 (1.00)
HAQ-DI (0–3) 0.31 (0.39) 0.40 (0.51) 0.38 (0.45) 0.36 (0.45)
MTX use, n (%) 190 (87.2) 176 (81.1) 189 (86.3) 555 (84.9)
MTX weekly dose (mg) 9.80 (3.33) 9.33 (3.05) 9.80 (2.97) 9.65 (3.13)
Other major DMARDs     
  Salazosulfapyridine, n (%) 44 (20.2) 59 (27.2) 49 (22.4) 152 (23.2)
  Bucillamine, n (%) 35 (16.1) 28 (12.9) 23 (10.5) 86 (13.1)
  Iguratimod, n (%) 14 (6.4) 12 (5.5) 11 (5.0) 37 (5.7)
  Tacrolimus, n (%) 2 (0.9) 10 (4.6) 5 (2.3) 17 (2.6)
  Gold sodium thiosulfate, n (%) 3 (1.4) 4 (1.8) 7 (3.2) 14 (2.1)
Glucocorticoid use, n (%) 69 (31.7) 73 (33.6) 68 (31.1) 210 (32.1)
  Glucocorticoid dose (mg/day) 3.73±1.89 3.96±2.16 4.10±2.27 3.93±2.11
NSAID use, n (%) 145 (66.5) 152 (70.0) 151 (68.9) 448 (68.5)
Hormone replacement therapy for 
osteoporosis treatment
0 (0.0) 2 (0.9) 1 (0.5) 3 (0.5)
Lumbar spine (L1–L4) BMD by machine type (g/cm2)   
  Hologic* 0.89 (0.16) 0.89 (0.16) 0.90 (0.16) 0.89 (0.16)
  Lunar* 1.11 (0.19) 1.01 (0.19) 1.02 (0.15) 1.05 (0.18)
CTX-I (ng/mL)† 0.46 (0.29, 0.59) 0.45 (0.28, 0.56) 0.48 (0.26, 0.64) 0.47 (0.28, 0.59)
COMP (U/L)† 9.43 (7.00, 11.40) 9.61 (7.80, 11.00) 9.58 (7.70, 11.50) 9.54 (7.45, 11.30)
CTX-II (ng/mmol Cre)† 397.09 (184.00, 480.00) 442.90 (189.00, 563.00) 389.27 (184.00, 457.00) 409.73 (184.00, 492.00)
n=number of patients who received ≥1 dose of study drug and had a baseline and at least 1 postbaseline measurement of the radiograph score.
Values are mean (SD) unless otherwise indicated.
*Hologic machine use: 142, 151 and 145 patients; Lunar machine use: 76, 66 and 74 patients; placebo, Q6M and Q3M, respectively.
†Values are medians (quartile 1, quartile 3).
ACPA, anticyclic citrullinated peptide antibody; BMD, bone mineral density; BMI, body mass index; COMP, cartilage oligomeric matrix protein; CRP, C reactive protein; CTX-I, 
C-telopeptide of type I collagen; CTX-II, C-telopeptide of type II collagen; Cre, creatinine; DAS, disease activity score; DMARDs, disease-modifying antirheumatic drugs; HAQ-DI, 
Health Assessment Questionnaire-Disability Index; JSN, joint space narrowing; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; Q3M, every 3 months; Q6M, 
every 6 months; RA, rheumatoid arthritis; RF, rheumatoid factor.
0.0001, respectively). At 6 months, only the Q3M group showed 
a significantly lower result in the erosion score versus placebo 
(p=0.0002) (figure 2B). Overall, the changes in the JSN score 
from baseline to 12 months were not significantly different 
among groups (figure 2C).
Cumulative probability plots for changes in the mTSS, erosion 
score and JSN score at 12 months are shown in figure 3. The 
proportions of patients without radiographic progression at 
12 months were greater in the denosumab groups versus the 
placebo group: 64.2% in the placebo group (140/218), 75.6% in 
the Q6M group (164/217; p=0.0097) and 78.1% in the Q3M 
group (171/219; p=0.0014). Likewise, significant increases in 
the proportions of patients without progression of radiographic 
erosion (change in erosion score ≤0.5) were observed in both 
denosumab groups. The proportions of patients with progres-
sion of JSN were similar among the groups. The proportions of 
patients with rapid radiographic progression at 12 months in the 
placebo, Q6M and Q3M groups were 10.6% (23/218), 6.9% 
(15/217; p=0.1785 vs placebo) and 5.0% (11/219; p=0.0310 
vs placebo), respectively.
The per cent changes in lumbar spine (L1–L4) BMD from 
baseline to 12 months were −1.03%, 3.99% and 4.88% in the 
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Figure 2 Mean changes from the baseline in the radiographic scores by the van der Heijde-modified Sharp method. (A) Modified total Sharp 
score, (B) modified Sharp erosion score and (C) modified Sharp joint space narrowing score. Missing values were imputed using linear extrapolation/
interpolation. Mean and 95% CIs are presented. P values were calculated by two-sided van Elteren stratified rank test adjusting for baseline use of 
glucocorticoid. BL, baseline; n, number of patients who received ≥1 dose of investigational product and had a baseline and at least one postbaseline 
measurement of the radiograph score; Q3M, every 3 months; Q6M, every 6 months.
placebo, Q6M and Q3M groups, respectively (p<0.0001 for 
both denosumab groups vs placebo) (figure 4A). Lumbar spine 
(L1–L4) BMD was significantly increased in the denosumab 
groups versus the placebo group, regardless of glucocorticoid 
use or osteoporosis (p<0.0001 for both subgroups vs placebo) 
(figure 4B and C).
Denosumab treatment significantly decreased the bone metab-
olism marker CTX-I level at 1 month, and the decrease was 
maintained over the study period (online supplementary file 1A). 
Urine CTX-II/Cre was decreased by both doses of denosumab 
for the first 3 months; thereafter, a decrease was observed only 
in the Q3M group (online supplementary file 1B). However, 
denosumab showed no effect on the cartilage turnover serum 
marker COMP (online supplementary file 1C).
No significant differences were observed between groups in 
the ACR20/50/70 at 12 months (online supplementary file 2). 
No significant changes in the DAS28-CRP or DAS28-ESR at 12 
months were observed. Changes in the HAQ-DI at 12 months 
were only significant in the Q6M group (−0.09, p=0.0028). 
Post hoc analysis revealed that the proportions of patients with 
minimal clinically important progression of HAQ-DI (≥0.22)21 
were lower in both denosumab groups versus the placebo 
group.
safety
The incidence of all adverse events was similar among the groups, 
except for stomatitis, which was observed more frequently in 
the denosumab groups (table 2). One death was reported due to 
interstitial lung disease in the Q3M group. This was judged to be 
drug related; however, the patient was known to have rheumatic 
interstitial pneumonia concomitantly.
dIsCussIOn
RA is a systemic autoimmune inflammatory disease that causes 
joint destruction and osteoporosis, primarily through osteoclast 
activation.3 4 We conducted this phase 3 study to evaluate the 
efficacy and safety of denosumab in patients with RA, in whom 
disease activity can be controlled by 1 year treatment with 
csDMARDs irrespective of whether they were receiving gluco-
corticoids. In this study, denosumab significantly inhibited the 
progression of joint destruction and increased lumbar spine 
BMD in patients receiving concomitant csDMARD treatment. 
These results are consistent with those of previous research in 
patients with RA.11 12
Overall efficacy assessment
Although the effects of Q3M versus Q6M regimens were not 
compared in this study, the data for the Q3M regimen were 
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Figure 3 Cumulative probability plots of changes from the baseline in the radiographic score at 12 months. (A) Modified total Sharp score, (B) 
modified Sharp erosion score and (C) modified Sharp joint space narrowing score. n, number of patients who received ≥1 dose of investigational 
product and had a baseline and at least one postbaseline measurement of the radiograph score; Q3M, every 3 months; Q6M, every 6 months.
better than those for the Q6M regimen in all the mean changes 
at 12 months, the percentage of progression-free patients 
(ΔmTSS≤0.5), the proportion of rapid radiographic progression 
and the per cent change in BMD. Notably, progression of mTSS 
was lower with the Q3M regimen versus the Q6M regimen, 
suggesting that the Q3M regimen is numerically more effective.
Progression of joint damage is irreversible, and the small 
amounts accrued over 1 year can gradually accumulate, causing 
extensive damage. Moreover, radiographic damage is related to 
clinical outcomes important to patients such as work and physical 
function. Therefore, preventing joint destruction is important. 
Denosumab suppressed the mean change in mTSS (0.72 in the 
Q3M group) and increased the proportion of patients without 
mTSS progression (78.1% in the Q3M group). However, true 
clinical relevance cannot be assessed over the short duration of 
a trial.
Comparison with studies of bDMARDS is difficult as demo-
graphic factors and populations are different. However, the 
Certolizumab–Optimal Prevention of joint damage for Early RA 
study of certolizumab reported a mean change in mTSS in week 
52 of 1.58 and 0.36, and a proportion of subjects with mTSS 
≤0.5 of 70.7% and 82.9% in the placebo and certolizumab 
groups, respectively.22
Denosumab suppressed joint margin erosion but did not block 
JSN or affect the proportion of patients without JSN change, 
compared with placebo. Furthermore, we found no significant 
differences in key indicators of disease activity. Denosumab did 
not affect the cartilage turnover marker serum COMP, although 
a clear inhibition was observed for bone metabolism markers. 
These results were consistent with past studies.11 12 Accordingly, 
distinct from DMARDs, we can conclude that denosumab did 
not exert an anti-inflammatory effect in patients with RA. These 
observations were expected, given that denosumab has only been 
shown to inhibit RANKL–receptor activator of nuclear factor κB 
(RANK) signalling during osteoclastogenesis, without affecting 
other inflammatory pathways.10
Functional assessment
The HAQ-DI assesses physical functional status in adults with 
arthritis and correlates with the disease activity score.23 In this 
study, no clinically meaningful improvement in the HAQ-DI 
was obtained, consistent with the finding that denosumab has 
no effect on disease activity. As joint destruction assessed by the 
mTSS correlates with functional disability over time,24 denos-
umab seems likely to have a preferential effect on physical func-
tion. Therefore, evaluating the long-term effects of denosumab 
in this area may be worthwhile.
effects on lumbar spine bMd
Individuals with RA have an increased risk of bone loss and 
fracture.3 4 In this study, denosumab prevented a decrease in 
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Figure 4 Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline 
use of glucocorticoid (B) and patients stratified by osteoporosis status (C). Data are for full analysis set (observed data). Coloured bars show least 
square mean values. P values are calculated using the analysis of covariance model after adjusting for treatment, baseline value, machine type, 
baseline value-by-machine type interaction and baseline use of glucocorticoid. Q3M, every 3 months; Q6M, every 6 months.
lumbar spine BMD and significantly increased the BMD. This 
increase was observed regardless of glucocorticoid use or base-
line osteoporosis, as has been reported previously.25 Patients at 
risk of osteoporosis tend to be treated with bisphosphonates, 
which inhibit osteoclastic bone resorption,26 but non-adherence 
reduces its efficacy.27 Annually administered parenteral zoledro-
nate could be superior to oral bisphosphonates due to improved 
compliance; notably, only zoledronate has been reported to 
suppress progression of bone erosions in patients with RA.28 
One study showed that denosumab prevents bone erosion, but 
alendronate had no effect.29 Another reported that denosumab 
was more effective than zoledronate for menopause-related 
osteoporosis.30 The differences in effects between bisphospho-
nates and denosumab may be explained by their distributions 
and mechanisms of action.31 Bisphosphonates are preferentially 
distributed in the gaps of bone resorption present in trabecular 
bone, taken up by osteoclasts and inhibit bone resorption with 
greater effect on cancellous bone. In contrast, denosumab is 
distributed throughout the extravascular space, without binding 
to the bone surface, inhibiting bone remodelling in both cortical 
and cancellous bone by blocking the RANKL–RANK interaction, 
a common pathway for osteoclast differentiation in osteopo-
rosis and inflammation. Denosumab is the first drug shown to 
have potent suppressive effects on both osteoporosis and joint 
destruction in patients with RA who are concomitantly receiving 
csDMARDs. As osteoporosis and joint destruction have been 
observed in some patients with RA treated with bDMARDS,32 
and because bDMARDs are contraindicated in some patients 
due to infection risk or costs, a combination of csDMARDs 
and denosumab could be a new treatment option for patients in 
whom csDMARDs are used to control disease activity.
safety profile
The incidence of adverse events was similar across treatment 
groups. Specifically, hypocalcemia, an identified risk of deno-
sumab,33 and fractures were comparable between groups. 
Overall, the safety profile of each denosumab group was broadly 
comparable to the placebo group, consistent with previous 
studies.11 12 33
study limitations
This study has some limitations, including the prohibited 
concomitant use of biologics and tofacitinib and the short study 
duration. This short duration was chosen for ethical reasons: 
to treat patients optimally in the placebo group. We conducted 
an open-label extension study following the phase 3 study to 
evaluate long-term effects and are planning a follow-up study of 
patients who completed the phase 3 extension study to assess the 
rebound effects and safety of denosumab on bone erosion and 
BMD in patients with RA.
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Table 2 Summary of adverse events
Aes, n (%)
Placebo
(n=224)
denosumab
60 mg Q6M
(n=221)
60 mg Q3M
(n=222)
Patients with adverse events 186 (83.0) 187 (84.6) 185 (83.3)
  Patients with serious adverse events 13 (5.8) 19 (8.6) 19 (8.6)
  Patients with related adverse events* 38 (17.0) 38 (17.2) 36 (16.2)
  Patients with related serious adverse events* 3 (1.3) 4 (1.8) 4 (1.8)
  Death 0 (0.0) 0 (0.0) 1 (0.5)
Any adverse events in ≥5% of patients in any treatment group  
  Nasopharyngitis 73 (32.6) 79 (35.7) 69 (31.1)
  Pharyngitis 16 (7.1) 13 (5.9) 16 (7.2)
  Influenza 12 (5.4) 8 (3.6) 10 (4.5)
  Stomatitis 13 (5.8) 22 (10.0) 27 (12.2)
  Dental caries 9 (4.0) 12 (5.4) 7 (3.2)
  Back pain 7 (3.1) 5 (2.3) 12 (5.4)
  Upper respiratory tract inflammation 9 (4.0) 18 (8.1) 8 (3.6)
  Hepatic function abnormal 20 (8.9) 14 (6.3) 13 (5.9)
Drug-related serious adverse events*
  Lymphoproliferative disorder 0 (0.0) 0 (0.0) 1 (0.5)
  Rectal cancer 0 (0.0) 0 (0.0) 1 (0.5)
  Squamous cell carcinoma of lung 0 (0.0) 1 (0.5) 0 (0.0)
  Lung neoplasm malignant 1 (0.4) 0 (0.0) 0 (0.0)
  Interstitial lung disease 0 (0.0) 1 (0.5) 1 (0.5)
  Abscess jaw 0 (0.0) 1 (0.5) 0 (0.0)
  Diverticulitis 1 (0.4) 0 (0.0) 0 (0.0)
  Ventricular tachycardia 0 (0.0) 0 (0.0) 1 (0.5)
  Platelet count decreased 0 (0.0) 0 (0.0) 1 (0.5)
  Brain stem infarction 0 (0.0) 1 (0.5) 0 (0.0)
  Sudden hearing loss 1 (0.4) 0 (0.0) 0 (0.0)
n=Number of patients who received ≥1 dose of investigational product. Classifications of adverse events are based on the Medical Dictionary for Regulatory Activities. Only 
includes treatment-emergent adverse events.
*This includes events for which the investigator indicated there was a reasonable possibility they may have been caused by the investigational product.
MACE, major adverse cardiovascular events; Q3M, every 3 months; Q6M, every 6 months.
Clinical impact and future potential
Currently, not all patients with RA receive treatment to suffi-
ciently suppress joint destruction for many reasons. Due to safety 
concerns, csDMARDs have a dose limit, and some csDMARDs 
cannot be combined. Furthermore, biologics are not used in all 
patients who insufficiently respond to csDMARDs for safety 
or economic reasons, even if indicated.34 In clinical trials using 
denosumab, no additive anti-inflammatory effect was observed 
in patients with RA, but its inhibitory effect on joint destruction 
was confirmed by use in combination with csDMARDs. Hence, 
we believe that this drug is a novel treatment option for patients 
with RA who do not respond well to csDMARDs, are unable to 
adjust or start other DMARDs due to safety concerns or costs or 
require treatment for osteoporosis.
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